Premium
Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti‐inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors
Author(s) -
Venerito M.,
Schneider C.,
Costanzo R.,
Breja R.,
Röhl F.W.,
Malfertheiner P.
Publication year - 2018
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14652
Subject(s) - medicine , aspirin , gastroenterology , proton pump inhibitor , helicobacter pylori , peptic , famotidine , peptic ulcer
Summary Background Nonsteroidal anti‐inflammatory drugs, low‐dose aspirin, non‐aspirin antiplatelet agents, anticoagulants, selective serotonin reuptake inhibitors and corticosteroids increase the risk of gastroduodenal bleeding. Aim To determine in a retrospective cohort study the contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients taking these drugs. Methods Among patients with peptic ulcer disease diagnosed by endoscopy from 01/2004 to 12/2014 (N = 1719, 60% males, age 65.8 ± 14.5), 56.9% had peptic ulcer bleeding (cases) and 43.1% uncomplicated peptic ulcer disease (controls). Demographics, intake of nonsteroidal anti‐inflammatory drugs, aspirin, non‐aspirin antiplatelet agents, anticoagulants, selective serotonin reuptake inhibitors, proton pump inhibitors and corticosteroids were documented. H. pylori status was determined by histology, rapid urease test or serology. Adjusted odds ratios ( OR ) were estimated by logistic regression analysis. Results Helicobacter pylori infection increased the risk of peptic ulcer bleeding in nonsteroidal anti‐inflammatory drug and aspirin users ( OR = 2.91, 95% CI = 1.71‐4.98 and OR = 2.23, 95% CI = 1.52‐3.28, respectively), but not in patients on anticoagulants, selective serotonin reuptake inhibitor or corticosteroid therapy. H. pylori‐ positive status substantially increased the risk of peptic ulcer bleeding in patients on non‐aspirin antiplatelet agents ( OR = 4.37, 95% CI = 1.28‐14.99), concomitant aspirin/nonsteroidal anti‐inflammatory drug intake ( OR = 5.85, 95% CI = 1.68‐20.36) and combined antiplatelet therapy ( OR = 8.43, 95% CI = 1.09‐65.17). After further adjustment for proton pump inhibitor intake, H. pylori infection was still a risk factor for peptic ulcer bleeding in nonsteroidal anti‐inflammatory drug and aspirin users. Conclusions Helicobacter pylori infection increases the risk of peptic ulcer bleeding in peptic ulcer disease patients on nonsteroidal anti‐inflammatory drugs, aspirin and non‐aspirin antiplatelet agents. H. pylori ‐positive patients on combined antiplatelet therapy carry the highest risk for peptic ulcer bleeding.